Phase II and coagulation cascade biomarker study of bevacizumab with or without docetaxel in patients with previously treated metastatic pancreatic adenocarcinoma

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 34, Issue 1, 2011, Pages 70-75

  Astsaturov, Igor A ^a   Meropol, Neal J ^b   Alpaugh, R Katherine ^a   Burtness, Barbara A ^a   Cheng, Jonathan D ^a   McLaughlin, Sue ^a   Rogatko, André ^c   Xu, Zhiheng ^d   Watson, James C ^a   Weiner, Louis M ^e   Cohen, Steven J ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d EMORY UNIVERSITY   (United States)

^e GEORGETOWN UNIVERSITY   (United States)

Author keywords

bevacizumab; coagulation system; docetaxel; pancreatic adenocarcinoma; second line chemotherapy

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR RECEPTOR; BEVACIZUMAB; D DIMER; DOCETAXEL; GEMCITABINE; THROMBIN ANTITHROMBIN COMPLEX; VASCULOTROPIN;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BLOOD CLOTTING; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CHOLANGITIS; DEEP VEIN THROMBOSIS; DEHYDRATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; ENDOTHELIUM CELL; EPIPHORA; FATIGUE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPERURICEMIA; HYPOALBUMINEMIA; INJECTION SITE REACTION; INTESTINE PERFORATION; LEUKOPENIA; LIVER ABSCESS; LUNG EMBOLISM; MALE; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAIL; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PARESTHESIA; PERITONITIS; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR VASCULARIZATION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; BLOOD COAGULATION FACTORS; DEOXYCYTIDINE; FEMALE; HUMANS; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PERITONEAL NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 79951678333     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3181d2734a     Document Type: Article

References (41)

1. Burris HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403-2413. (Pubitemid 27251144)
2. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960-1966 (Pubitemid 46972777)
3. Reni M, Berardi R, Mambrini A, et al. A multi-centre retrospective review of second-line therapy in advanced pancreatic adenocarcinoma. Cancer Che-mother Pharmacol. 2008;62:673-678.
4. Ulrich-Pur H, Raderer M, Verena Kornek G, et al. Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma. Br J Cancer. 2003;88:1180-1184. (Pubitemid 36606330)
5. Gebbia V, Maiello E, Giuliani F,et al. Second-line chemotherapy in advanced pancreatic carcinoma: a multicenter survey of the Gruppo Oncologico Italia Meridionale on the activity and safety of the FOLFOX4 regimen in clinical practice. Ann Oncol. 2007;18(suppl 6):vi124-vi127.
6. Tsavaris N, Kosmas C, Skopelitis H, et al. Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: a phase II study. Invest New Drugs. 2005;23:369-375. (Pubitemid 40980360)
7. Shojaei F, Ferrara N. Antiangiogenesis to treat cancer and intraocular neo-vascular disorders. Lab Invest. 2007;87:227-230. (Pubitemid 46353946)
8. Chung GG, Yoon HH, Zerkowski MP, et al. Vascular endothelial growth factor, FLT-1, and FLK-1 analysis in a pancreatic cancer tissue microarray. Cancer. 2006;106:1677-1684.
9. Riess H. Antiangiogenic strategies in pancreatic cancer. Recent Results Cancer Res. 2008;177:123-129.
10. Khorana AA, Ahrendt SA, Ryan CK, et al. Tissue factor expression, angio-genesis, and thrombosis in pancreatic cancer. Clin Cancer Res. 2007;13: 2870-2875. (Pubitemid 46849560)
11. Tsopanoglou NE, Maragoudakis ME. Role of thrombin in angiogenesis and tumor progression. Semin Thromb Hemost. 2004;30:63-69. (Pubitemid 38457301)
12. Trikha M, Nakada MT. Platelets and cancer: implications for antiangiogenic therapy. Semin Thromb Hemost. 2002;28:39-44. (Pubitemid 34194871)
13. Gora-Tybor J, Jamroziak K, Szmigielska-Kaplon A, et al. Evaluation of circulating endothelial cells as noninvasive marker of angiogenesis in patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2009;50:62-67.
14. Shaked Y, Henke E, Roodhart JM, et al. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell. 2008;14:263-273.
15. Bremnes RM, Camps C, Sirera R. Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer. 2006;51:143-158. (Pubitemid 43144358)
16. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group study E3200. J Clin Oncol. 2007;25:1539-1544. (Pubitemid 46733080)
17. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342. (Pubitemid 38702844)
18. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666-2676.
19. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542-2550. (Pubitemid 44917502)
20. Rougier P, Adenis A, Ducreux M, et al. A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma. Eur J Cancer. 2000;36:1016-1025. (Pubitemid 30316427)
21. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
22. Rogatko A, Babb JS, Wang H, et al. Patient characteristics compete with dose as predictors of acute treatment toxicity in early phase clinical trials. Clin Cancer Res. 2004;10:4645-4651. (Pubitemid 38955514)
23. Kindler HL, Niedzwiecki D, Hollis D, et al. A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): a preliminary analysis of Cancer and Leukemia Group B (CALGB). J Clin Oncol (Meeting Abstracts). 2007;25(suppl 18): 4508.
24. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004;10:145-147. (Pubitemid 38524883)
25. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669-676. (Pubitemid 36749215)
26. Ferrara N, Hillan KJ, Gerber HP, et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3:391-400. (Pubitemid 38618122)
27. Pelzer U, Kubica K, Stieler J, et al. A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study. J Clin Oncol (Meeting Abstracts). 2008;26(suppl 15):4508.
28. Kindler HL, Friberg G, Singh DA, et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2005;23:8033-8040. (Pubitemid 46657405)
29. Heinzerling JH, Huerta S. Bowel perforation from bevacizumab for the treatment of metastatic colon cancer: incidence, etiology, and management. Curr Surg. 2006;63:334-337. (Pubitemid 44340939)
30. Nalluri SR, Chu D, Keresztes R, et al. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA. 2008;300:2277-2285.
31. Tetzlaff ED, Correa AM, Baker J, et al. The impact on survival of thrombo-embolic phenomena occurring before and during protocol chemotherapy in patients with advanced gastroesophageal adenocarcinoma. Cancer. 2007;109: 1989-1995. (Pubitemid 46744192)
32. Kuderer NM, Khorana AA, Lyman GH, et al. A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications. Cancer. 2007;110:1149-1161. (Pubitemid 47312882)
33. Altiay G, Ciftci A, Demir M, et al. High plasma D-dimer level is associated with decreased survival in patients with lung cancer. Clin Oncol (R Coll Radiol). 2007;19:494-498. (Pubitemid 47181178)
34. Antoniou D, Pavlakou G, Stathopoulos GP, et al. Predictive value of D-dimer plasma levels in response and progressive disease in patients with lung cancer. Lung Cancer. 2006;53:205-210. (Pubitemid 43994226)
35. Buccheri G, Torchio P, Ferrigno D. Plasma levels of D-dimer in lung carcinoma: clinical and prognostic significance. Cancer. 2003;97:3044-3052. (Pubitemid 36676259)
36. Gadducci A, Marrai R, Baicchi U, et al. Preoperative D-dimer plasma assay is not a predictor of clinical outcome for patients with advanced ovarian cancer. Gynecol Oncol. 1997;66:85-88. (Pubitemid 27329313)
37. Dirix LY, Salgado R, Weytjens R, et al. Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer. Br J Cancer. 2002;86:389-395. (Pubitemid 34185123)
38. Garcia-Avello A, Galindo-Alvarez AJ, Martinez-Molina E, et al. Coagulative system activation and fibrinolytic system inhibition activities arise from tumoral draining vein in colon carcinoma. Thromb Res. 2001;104:421-425. (Pubitemid 34084809)
39. Gouin-Thibault I, Achkar A, Samama MM. The thrombophilic state in cancer patients. Acta Haematol. 2001;106:33-42. (Pubitemid 32830514)
40. Shaked Y, Ciarrocchi A, Franco M, et al. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science. 2006;313:1785-1787. (Pubitemid 44454154)
41. Beaudry P, Force J, Naumov GN, et al. Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endo-thelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity. Clin Cancer Res. 2005;11:3514-3522. (Pubitemid 40627906)